21 C.F.R. § 601.50

Confidentiality of data and information in an investigational new drug notice for a biological product.

Last amended: 2016Year: 2026Length: 106 wordsSubsections: 3Official source

Cite as 21 C.F.R. § 601.50 (2026)

(a) The existence of an IND notice for a biological product will not be disclosed by the Food and Drug Administration unless it has previously been publicly disclosed or acknowledged. (b) The availability for public disclosure of all data and information in an IND file for a biological product shall be handled in accordance with the provisions established in § 601.51. (c) Notwithstanding the provisions of § 601.51, the Food and Drug Administration shall disclose upon request to an individual on whom an investigational biological product has been used a copy of any adverse reaction report relating to such use. [39 FR 44656, Dec. 24, 1974]
Cross-references to the CFR
601.51601.51.
21 C.F.R. § 601.50: Confidentiality of data and information in an investigational new drug notice for a biological product. | Justis AI